Connect
← Return to John Hopkins Webinar on transplant recipients and vaccines
Discussion
John Hopkins Webinar on transplant recipients and vaccines
Transplants | Last Active: Jan 13, 2022 | Replies (141)Comment receiving replies
@snorris, Thank you for the link to the interview. It is very helpful and has given me the information in clear understandable terms.
Welcome to Connect. I can see that you have ben a member for a while, and that this is your first post. I am glad that you chose to jump in with this information.
Are you a transplant recipient?
Replies to "@snorris, Thank you for the link to the interview. It is very helpful and has given..."
Evidently Tacrolimus is a prophylactic for Covid 19 in preventing sever infection.
Tacrolimus is immunosuppressive by inhibiting calcineurin, and suppressing the early phase of T-cell activation, and the expression of many cytokines (IL-2, IL-4, TNF-α and IFN-γ) that are needed in the activation of the cellular immune response, possibly preventing a cytokine storm as observed in severe COVID-19.Jun 27, 2020
https://www.ncbi.nlm.nih.gov › pmc
Calcineurin inhibitors revisited: A new paradigm for COVID-19? - NCBI - NIH
Connect
Hi Rosemary. My husband received his new liver at Mayo Rochester in October 2018. It’s been a long road, 33 days in hospital post transplant, he’s doing well now, and we have found this forum very helpful.